Stock RCAR RENOVACARE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials RenovaCare, Inc.

Equities

RCAR

US75988J1060

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 02:48:44 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.0001 USD 0.00% Intraday chart for RenovaCare, Inc. 0.00% +9,900.00%
2022 RenovaCare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
2022 RenovaCare, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization 1 149.7 370.8 111.4 279.5 244.6 24.41
Enterprise Value (EV) 1 149.5 369 96.02 267.3 237.3 21.6
P/E ratio -71.9 x -98.2 x -53.2 x -83.1 x -25.6 x -5.46 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -78.7 x -137 x -47.8 x -72.4 x -24.5 x -4 x
EV / FCF -164 x -963 x -77.1 x -124 x -173 x -6.22 x
FCF Yield -0.61% -0.1% -1.3% -0.81% -0.58% -16.1%
Price to Book 627 x 223 x 8.25 x 23 x 34.6 x 10.4 x
Nbr of stocks (in thousands) 69,956 76,145 76,841 87,352 87,352 87,352
Reference price 2 2.140 4.870 1.450 3.200 2.800 0.2795
Announcement Date 3/28/17 3/13/18 4/12/19 5/14/20 3/31/21 3/30/22
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales - - - - - -
EBITDA 1 -1.898 -2.696 -2.008 -3.69 -9.674 -5.4
EBIT 1 -1.898 -2.696 -2.008 -3.69 -9.677 -5.409
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -2.078 -3.689 -2.121 -3.358 -9.548 -4.472
Net income 1 -2.078 -3.689 -2.121 -3.358 -9.548 -4.472
Net margin - - - - - -
EPS 2 -0.0298 -0.0496 -0.0273 -0.0385 -0.1093 -0.0512
Free Cash Flow 1 -0.911 -0.3832 -1.245 -2.161 -1.368 -3.475
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/28/17 3/13/18 4/12/19 5/14/20 3/31/21 3/30/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 - - - - - -
Net Cash position 1 0.25 1.87 15.4 12.2 7.33 2.82
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.91 -0.38 -1.24 -2.16 -1.37 -3.47
ROE (net income / shareholders' equity) -895% -388% -25% -24.4% -99.3% -94.9%
ROA (Net income/ Total Assets) -204% -92% -13.4% -16.4% -58.1% -56.1%
Assets 1 1.019 4.011 15.87 20.5 16.45 7.968
Book Value Per Share 2 0 0.0200 0.1800 0.1400 0.0800 0.0300
Cash Flow per Share 2 0.0100 0.0400 0.1800 0.1400 0.0800 0.0300
Capex 1 0 - - - 0.04 -
Capex / Sales - - - - - -
Announcement Date 3/28/17 3/13/18 4/12/19 5/14/20 3/31/21 3/30/22
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RENOVACARE, INC. Stock RenovaCare, Inc.
+9,900.00% 8.74K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RCAR Stock
  4. Financials RenovaCare, Inc.